Results 201 to 210 of about 14,917 (246)

New Drugs: Eplerenone

Australian Prescriber, 2005
openaire   +1 more source

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Zhang Y, Bao YC, Wang LX, Zhao HJ, Sun J, Sun L, Duan W, Du M, Wang LJ, An QY, Yang WZ.   +10 more
europepmc   +1 more source

Current Application of Mineralocorticoid Antagonist (MRA) in Heart Failure and CKD: Does Non-Steroidal Drug Add Novel Insights. [PDF]

Biomedicines
Carlino I, Pirrotta F, Gennari L, Palazzuoli A.   +3 more
europepmc   +1 more source

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis. [PDF]

Front Cardiovasc Med
Yu W, Luo F, Rao J, Lei G, Wu Q, Shen W, Yang P, Li P.   +7 more
europepmc   +1 more source

Aldosterone in Chronic Kidney Disease. [PDF]

Biomedicines
Polenus P, Đuran A, Karanović Štambuk S.   +2 more
europepmc   +1 more source

Isolated left ventricular apical hypoplasia: a case report. [PDF]

Eur Heart J Case Rep
Tulluri U, Suvarna T, Barhate G.
europepmc   +1 more source

Causal effects of primary aldosteronism on inflammation and bone density: evidence from Mendelian randomization, animal, and clinical studies. [PDF]

Diabetol Metab Syndr
Zhang Z, Du Y, Zhang F, Li X, Rong L, Zhu H, Tan J, Huang J.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ethics and eplerenone

Journal of Medical Ethics, 2012
The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive therapy be included as a comparator when the expensive therapy ...
Shruti, Gupta, Adriane J, Fugh-Berman, Anthony, Scialli   +2 more
openaire   +2 more sources